Mark Peter Ridgill
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Peter Ridgill.
Bioorganic & Medicinal Chemistry Letters | 2001
Kevin Dinnell; Gary G. Chicchi; Madhumeeta J Dhar; Jason Matthew Elliott; Gregory John Hollingworth; Marc M. Kurtz; Mark Peter Ridgill; Wayne Rycroft; Kwei-Lan Tsao; Angela R. Williams; Christopher John Swain
Novel 2-aryl indole hNK1 receptor ligands were prepared utilising palladium cross-coupling chemistry of a late intermediate as a key step. Compounds with high hNK1 receptor binding affinity and good brain penetration (e.g., 9d) were synthesised.
Bioorganic & Medicinal Chemistry Letters | 1999
Neil Roy Curtis; Janusz Jozef Kulagowski; Paul D. Leeson; Mark Peter Ridgill; Frances Emms; Stephen B. Freedman; Shil Patel; Smita Patel
7-azaindole compounds bearing a cyclic amine moiety linked by a one or two carbon chain attached at the 2- or 3-position were synthesised and evaluated as potential dopamine D4 ligands. Highest affinity and selectivity for the D4 receptor resided in the 3-aminomethyl-7-azaindole series.
Bioorganic & Medicinal Chemistry Letters | 1993
Paul D. Leeson; Raymond Baker; Robert W. Carling; Janusz Jozef Kulagowski; Ian M. Mawer; Mark Peter Ridgill; Michael Rowley; Julian D. Smith; Ian Stansfield; Graeme Irvine Stevenson; Alan C. Foster; John A. Kemp
Abstract 3-Substituted-2-quinoloners ( 6–8 ) have been identified as glycine-site N-methyl-D-aspartate receptor antagonists. It is proposed that the α-phenyl lactam unit in the potent 4-hydroxy-3-phenyl derivatives ( 7d and 8b , L-701,315) may act as a glycine bioisostere in receptor recognition.
Bioorganic & Medicinal Chemistry Letters | 2002
Jason Matthew Elliott; José L. Castro; Gary G. Chicchi; Laura Catherine Cooper; Kevin Dinnell; Gregory John Hollingworth; Mark Peter Ridgill; Wayne Rycroft; Marc M. Kurtz; Duncan E. Shaw; Christopher John Swain; Kwei-Lan Tsao; Lihu Yang
Abstract A series of novel 4,4-disubstituted cyclohexylamine based NK 1 antagonists is described. The effect of changes to the C 1 –C 4 relative stereochemistry on the cyclohexane ring and replacements for the flexible linker are discussed, leading to the identification of compounds with high affinity and good in vivo duration of action.
Bioorganic & Medicinal Chemistry Letters | 1996
Neil Roy Curtis; Janusz Jozef Kulagowski; Paul D. Leeson; Ian M. Mawer; Mark Peter Ridgill; Michael Rowley; Sarah Grimwood; George Marshall
Abstract A series of analogues of the novel diiodotyrosine derived NMDA glycine-site ligand (R)-4 was prepared in which the aryl substitution, chain length and amino acid groups were varied. The key structural features for binding are the α-amino acid function, having the (R) absolute stereochemistry, the 3,5-diiodo substituted aromatic ring and a lipophilic group attached at the phenolic oxygen of the tyrosine moiety.
Bioorganic & Medicinal Chemistry Letters | 1997
Karen Elizabeth Haworth; Timothy Harrison; Janusz Jozef Kulagowski; Paul D. Leeson; Andrew Pate Owens; Mark Peter Ridgill; Martin Richard Teall; M. Fielding; Kevin T. Chapman; Frances Emms; Rosemary Marwood; Shil Patel; K.L. Moss
Abstract A series of 1,2,3,6-tetrahydropyridines 3 were synthesised, which resulted in selective high affinity dopamine D4 ligands. The SAR of heterocyclic replacements and aromatic substitution was investigated, leading to compounds of nanomolar binding affinity with excellent selectivity over both D2 and D3 receptors.
Bioorganic & Medicinal Chemistry Letters | 2001
Duncan Shaw; Gary G. Chicchi; Jason Matthew Elliott; Marc M. Kurtz; Denise Morrison; Mark Peter Ridgill; Nicola Szeto; Alan P. Watt; Angela R. Williams; Christopher John Swain
The in vivo properties of a series of 2-arylindole NK(1) antagonists have been improved, by modification of the amide substituent. The 1-(2-methoxyphenyl)piperazine amide was identified as a major area of metabolism in the lead compound 1. Replacement of this amine moiety by a 4-benzyl-4-hydroxypiperidine resulted in a compound 18 with reduced clearance and improved central duration of action.
Journal of Medicinal Chemistry | 1996
Janusz Jozef Kulagowski; Howard B. Broughton; Neil Roy Curtis; Ian M. Mawer; Mark Peter Ridgill; Baker R; Frances Emms; Stephen B. Freedman; Rosemarie Marwood; Shil Patel; Ragan Ci; Paul D. Leeson
Journal of Pharmacology and Experimental Therapeutics | 1997
Smita Patel; S. Freedman; K. L. Chapman; F. Emms; A. E. Fletcher; M. Knowles; R. Marwood; G. Mcallister; J. Myers; Neil Roy Curtis; Janusz Jozef Kulagowski; Paul D. Leeson; Mark Peter Ridgill; M. Graham; S. Matheson; D. Rathbone; Alan P. Watt; Linda J. Bristow; N. M. J. Rupniak; E. Baskin; J. J. Lynch; C. I. Ragan
Journal of Medicinal Chemistry | 1994
Kulagowski Jj; Baker R; Curtis Nr; Paul D. Leeson; Mawer Im; Moseley Am; Mark Peter Ridgill; Michael Rowley; Stansfield I; Alan C. Foster